The angiotensin II (AII) inhibition cocktail has been developed by Bertin Pharma in order to fix physiological concentration of AII in biological samples, namely blood. Indeed, it has been observed that sample preparation is highly recommended when
The angiotensin II (AII) inhibition cocktail has been developed by Bertin Pharma in order to fix physiological concentration of AII in biological samples, namely blood. Indeed, it has been observed that sample preparation is highly recommended when
An angiotensin metabolite that functions as a type 1 angiotensin II receptor agonist whereupon it can control hydroelectrolyte balance and demonstrates vasodilatory and anti-inflammatory actions in opposition to various adverse effects of
An angiotensin metabolite that functions as a type 1 angiotensin II receptor agonist whereupon it can control hydroelectrolyte balance and demonstrates vasodilatory and anti-inflammatory actions in opposition to various adverse effects of
A selective agonist of FFAR3 (IC<sub>50</sub> = 117 nM) that does not activate the related receptor FFAR2 at concentrations up to 100 µM 10 µM stimulates a 1.26-fold increased release of glucagon-like peptide-1 from colonic crypt
A selective agonist of FFAR3 (IC<sub>50</sub> = 117 nM) that does not activate the related receptor FFAR2 at concentrations up to 100 µM 10 µM stimulates a 1.26-fold increased release of glucagon-like peptide-1 from colonic crypt
A selective ALK1 and ALK2 inhibitor (IC<sub>50</sub>s = 24 nM for each) with preference over ALK3 (IC<sub>50</sub> = 1.17 µM) and other related activin and TGF-&beta type I receptors (IC<sub>50</sub>s = 3, 0.
A selective ALK1 and ALK2 inhibitor (IC<sub>50</sub>s = 24 nM for each) with preference over ALK3 (IC<sub>50</sub> = 1.17 µM) and other related activin and TGF-&beta type I receptors (IC<sub>50</sub>s = 3, 0.
An orally bioavailable antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM) at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.
An orally bioavailable antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM) at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.
A selective agonist of FFAR3 (IC<sub>50</sub> = 117 nM) that does not activate the related receptor FFAR2 at concentrations up to 100 µM 10 µM stimulates a 1.26-fold increased release of glucagon-like peptide-1 from colonic crypt
A selective agonist of FFAR3 (IC<sub>50</sub> = 117 nM) that does not activate the related receptor FFAR2 at concentrations up to 100 µM 10 µM stimulates a 1.26-fold increased release of glucagon-like peptide-1 from colonic crypt
An orally bioavailable inhibitor of ACAT (IC<sub>50</sub>s = 24 and 9.2 µM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid
An orally bioavailable inhibitor of ACAT (IC<sub>50</sub>s = 24 and 9.2 µM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid
A broad-spectrum, indole-based antiviral compound that blocks viral fusion with target membranes, prohibiting viral entry into cells effective against numerous viruses, including influenza A, B, and C and hepatitis B and C (IC<sub>50</sub>s range
A broad-spectrum, indole-based antiviral compound that blocks viral fusion with target membranes, prohibiting viral entry into cells effective against numerous viruses, including influenza A, B, and C and hepatitis B and C (IC<sub>50</sub>s range
An angiotensin metabolite that functions as a type 1 angiotensin II receptor agonist whereupon it can control hydroelectrolyte balance and demonstrates vasodilatory and anti-inflammatory actions in opposition to various adverse effects of
An angiotensin metabolite that functions as a type 1 angiotensin II receptor agonist whereupon it can control hydroelectrolyte balance and demonstrates vasodilatory and anti-inflammatory actions in opposition to various adverse effects of